Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Executive Summary
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.